MOORESTOWN, N.J., May 30,2018 – Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company optimizing medication safety by deploying new, medication risk mitigation software solutions and proprietary medication decision support tools, announced two new executives have joined its corporate team.
Kim Browning, CHC, PMP, is TRHC’s new Executive Vice President (EVP) responsible for TRHC subsidiary company, Capstone Performance Systems and its new division that resulted from the recent acquisition of Peak Health Plan Management.
Most recently, Ms. Browning was EVP of Cognisight, LLC, in Rochester, New York, where she led business strategy and added new product and service lines. Her career has included leadership roles at several BlueCross BlueShield plans of NJ and Excellus Medicaid Plan in NY. During her tenure as the State Government Programs division head at Excellus BlueCross BlueShield, the plan was ranked #1 in New York and #3 nationally for Medicaid contractors in US News & World Report’s 2009 rankings of health plans. Ms. Browning graduated magna cum laude with dual degrees from State University College at Buffalo. She holds certifications in Healthcare Compliance (CHC), Project Management (PMP), and Healthcare Reform (CHRS). An author of several white papers on risk adjustment, Ms. Browning is a frequent speaker on the topic at industry meetings. She was named a Healthcare Benefit Academy Fellow in 2017.
Alan D. Stein, MD, PhD, joins TRHC as its Senior Vice President (SVP) for Healthcare Analytics. In this role, he will advance analytics and data science capabilities throughout the organization. Dr. Stein is a physician scientist with medical, technical and research training, complemented by industry and senior management experience and a passionate entrepreneurial spirit. Dr. Stein comes to TRHC from Hewlett Packard Enterprise (HPE), Palo Alto, California, where he led the development of a big-data analytics platform that helps healthcare systems improve clinical pathways and care delivery. Dr. Stein previously served as Chief Medical and Technology Officer for Zargis Medical Corp in Princeton, NJ. Dr. Stein received his PhD (Biophysics), MD and BS (Engineering) from the University of Pennsylvania. He has received numerous honors, awards and a United States patent. Dr. Stein is invited to speak on healthcare technology at diverse venues around the world.
“We are pleased and proud to have two such accomplished professionals join our executive ranks,” said Calvin H. Knowlton, PhD, Chairman and CEO of TRHC. “Ms. Browning will oversee the continued growth of our risk adjustment, coding, and now health plan management services. Dr. Stein is a seasoned executive recognized in healthcare technology development and commercialization for global and domestic markets. He is joining us to further the development of our proprietary software and tools to mitigate medication risk and improve medication safety. His data science experience will support TRHC’s ability to leverage its proprietary and rich dataset for research and the continued enhancement of our client experience with medication decision support services.”
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.